Celgene appoints new Human Resources director
pharmafile | January 2, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Celgene
Celgene has announced the appointment of Sarah Bater as director of Human Resources, Celgene UK and Ireland.
Bater brings a wealth of experience to her new role after holding a number of senior HR positions in a variety of companies including most recently BAA Ltd, where she was HR director for Policy, Process and Resourcing.
Previously, Bater worked at AstraZeneca as HR Business partner for the Specialist Care Directorate, followed by the role of head of HR Shared Services. During her time at AstraZeneca, she worked on a number of transformation programmes and focused on the evolution of Key Account Management.
Bater also spent time in Africa with Vodafone where she focused on embedding the HR Shared Services model and was part of the team that rolled out diversity and inclusion within HR and the business.
Bater said: “I am extremely excited to join Celgene in my role as HR director. Celgene is a company which has successfully established a dynamic and prosperous environment. I hope to bring my experience to the HR Team to help reinforce the great values Celgene already holds and ensure a culture where existing and future employees will thrive.”
Samantha Pearce, general manager of Celgene UK and Ireland added: “Celgene has gone through a period of fast-paced growth over the last few years, so we are delighted that Sarah, with her expertise in HR, will be joining our team. Her role reinforces our commitment to our employees, current and future, to help them grow professionally, whilst ensuring the Celgene culture is maintained.”
Related Content
NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …
NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …
NICE recommends Celgene’s Revlimid combo for follicular lymphoma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …
